Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.51 |
| ▸ | XBP1 | P17861 | 1/20 | 0.51 |
| ▸ | GLA | P06280 | 1/20 | 0.48 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.48 |
| ▸ | BLM | P54132 | 1/20 | 0.48 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.44 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12256755 | 0.92 | KDM4E (0.52) | KDM4EXBP1GLAADORA2BBLM | |
| SCHEMBL12257518 | 0.88 | ADORA1 (0.49) | GLAADORA2BBLMADORA2AADORA1 | |
| SCHEMBL12259556 | 0.85 | ADORA2A (0.59) | GLAADORA2BBLMADORA2AADORA1 | |
| SCHEMBL12257985 | 0.83 | ADORA1 (0.47) | GLAADORA2BBLMADORA2AADORA1 | |
| SCHEMBL12257425 | 0.83 | ADORA1 (0.47) | GLAADORA2BBLMADORA2AADORA1 | |
| SCHEMBL14082885 | 0.81 | ADORA2B (0.54) | KDM4EGLAADORA2BBLMADORA2A | |
| SCHEMBL12233678 | 0.81 | GLA (0.46) | GLAADORA2BBLMADORA2AADORA1 | |
| SCHEMBL12257948 | 0.81 | MAOB (0.52) | GLAADORA2BBLM | |
| SCHEMBL8184575 | 0.81 | ADORA2A (0.54) | KDM4EADORA2BADORA2AADORA1 | |
| SCHEMBL12257489 | 0.81 | ADORA2B (0.54) | KDM4EADORA2BADORA2AADORA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8044061-B2 | Parkinson's disease, catalepsy, dystonia, dyskinetic syndrome, restless legs syndrome, migraine, pain, dementia, neurodegenerative disorders, alcohol withdrawal and/or ischemic conditions such as e.g. stroke or cardiac ischemia. | UCB PHARMA GMBH (DE) | 2011-10-25 | — | — | US | disclosed |
| US-20080221134-A1 | 8-ALKYNYLXANTHINES AND DERIVATIVES | RHEINISCHE FRIEDRICH-WILHELMS-UNIVERSITAET BONN (DE) | 2008-09-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080221134-A1 | 8-ALKYNYLXANTHINES AND DERIVATIVES | SLC6A3, PARK7, SLC18A2 | KDM4E 3538/4885XBP1 4263/4885GLA 1605/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.